18 Jan EG 427
Philippe Chambon, M.D., Ph.D., CEO
April 16 | 4:00pm | Salone dei Cavalieri, Section 2
Paris, France
(Private)
EG 427 is developing DNA medicines based on non-replicative HSV-1 vectors for prevalent indications.
EG110A is our lead program currently in Ph1b/2a trial in neurogenic detrusor overactivity (NDO) delivering safety and efficacy read-out in this high-value indication(s) in early ’26. Our HERpes-based Modular Expression System (HERMES) platform is the foundation for a pipeline in multiple highly prevalent indications. nrHSV-1 vectors enable precision delivery of DNA medicines to specific groups of cells, have a strong track-record of success and safety in the clinic, can be re-administered, and have a cost per dose consistent with treatment of common diseases. The HERMES platform provides stable nrHSV-1 vectors to safety deliver large and complex DNA medicines to predefined specific targets with superior control and safety. We have early-stage programs in pain, neurodegenerative disease, neuromuscular disease, and oncology.
